2 597

Cited 24 times in

Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.

DC Field Value Language
dc.contributor.author박정엽-
dc.contributor.author방승민-
dc.contributor.author송시영-
dc.contributor.author정문재-
dc.contributor.author정재복-
dc.contributor.author김윤재-
dc.contributor.author박승우-
dc.date.accessioned2014-12-20T16:44:06Z-
dc.date.available2014-12-20T16:44:06Z-
dc.date.issued2011-
dc.identifier.issn0009-3157-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/93277-
dc.description.abstractBACKGROUND: Chemotherapy is a critical treatment option in advanced biliary tract cancer (BTC), which is often diagnosed at advanced stage and is therefore inoperable. The aim of this phase II trial was to evaluate the efficacy and safety of a combination therapy with gemcitabine and irinotecan as the first-line chemotherapy in patients with previously untreated advanced BTC. PATIENTS AND METHODS: Patients with pathologically confirmed advanced BTC received gemcitabine (1,000 mg/m(2) over 30 min) and irinotecan (100 mg/m(2) over 2 h) on days 1 and 8 every 3 weeks. RESULTS: Of 39 patients eligible for this trial, 6 had intrahepatic bile duct cancer, 2 had extrahepatic bile duct cancer and 31 had gallbladder cancer. A total of 193 cycles of chemotherapy were administered, with a median of 4 cycles per patient (range 1-18). The objective response rate was 20.5%, and the disease control rate was 66.7% in intention-to-treat analysis. The median progression-free survival was 4.3 months (95% CI 2.70-5.90), and overall survival was 7.6 months (95% CI 4.56-10.64). Grade 3 and 4 toxicities included anemia (20.5% of patients), thrombocytopenia (2.3%), neutropenia (10.3%), aspartate transaminase increase (10.3%), alanine transaminase increase (5.1%) and emesis (5.1%). CONCLUSION: Combination therapy of gemcitabine and irinotecan had an efficacy comparable to historic control and can be a viable treatment option. It was well tolerated by patients with advanced BTC.-
dc.description.statementOfResponsibilityopen-
dc.format.extent236~243-
dc.relation.isPartOfCHEMOTHERAPY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAlanine Transaminase/metabolism-
dc.subject.MESHAnemia/etiology-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHAspartate Aminotransferases/metabolism-
dc.subject.MESHBiliary Tract Neoplasms/drug therapy*-
dc.subject.MESHBiliary Tract Neoplasms/mortality-
dc.subject.MESHBiliary Tract Neoplasms/pathology-
dc.subject.MESHCamptothecin/administration & dosage-
dc.subject.MESHCamptothecin/analogs & derivatives*-
dc.subject.MESHCamptothecin/therapeutic use-
dc.subject.MESHDeoxycytidine/administration & dosage-
dc.subject.MESHDeoxycytidine/analogs & derivatives*-
dc.subject.MESHDeoxycytidine/therapeutic use-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeutropenia/etiology-
dc.subject.MESHPositron-Emission Tomography-
dc.subject.MESHSurvival Rate-
dc.subject.MESHThrombocytopenia/etiology-
dc.subject.MESHTomography, X-Ray Computed-
dc.titleProspective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorChung M.J.-
dc.contributor.googleauthorKim Y.J.-
dc.contributor.googleauthorPark J.Y.-
dc.contributor.googleauthorBang S.-
dc.contributor.googleauthorSong S.Y.-
dc.contributor.googleauthorChung J.B.-
dc.contributor.googleauthorPark S.W.-
dc.identifier.doi10.1159/000328021-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01647-
dc.contributor.localIdA01786-
dc.contributor.localIdA02035-
dc.contributor.localIdA03602-
dc.contributor.localIdA03706-
dc.contributor.localIdA00792-
dc.contributor.localIdA01551-
dc.relation.journalcodeJ00519-
dc.identifier.eissn1421-9794-
dc.identifier.pmid21597288-
dc.identifier.urlhttp://www.karger.com/Article/FullText/328021-
dc.subject.keywordBiliary tract cancer-
dc.subject.keywordChemotherapy-
dc.subject.keywordGemcitabineIrinotecan-
dc.contributor.alternativeNamePark, Jeong Youp-
dc.contributor.alternativeNameBang, Seung Min-
dc.contributor.alternativeNameSong, Si Young-
dc.contributor.alternativeNameChung, Moon Jae-
dc.contributor.alternativeNameChung, Jae Bock-
dc.contributor.alternativeNameKim, Yoon Jae-
dc.contributor.alternativeNamePark, Seung Woo-
dc.contributor.affiliatedAuthorPark, Jeong Youp-
dc.contributor.affiliatedAuthorBang, Seung Min-
dc.contributor.affiliatedAuthorSong, Si Young-
dc.contributor.affiliatedAuthorChung, Moon Jae-
dc.contributor.affiliatedAuthorChung, Jae Bock-
dc.contributor.affiliatedAuthorKim, Yoon Jae-
dc.contributor.affiliatedAuthorPark, Seung Woo-
dc.rights.accessRightsnot free-
dc.citation.volume57-
dc.citation.number3-
dc.citation.startPage236-
dc.citation.endPage243-
dc.identifier.bibliographicCitationCHEMOTHERAPY, Vol.57(3) : 236-243, 2011-
dc.identifier.rimsid27109-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.